We invest in programs that aim to eliminate some of the world's most challenging public health threats, enable access to medicines and help fight the stigma that prevent people from seeking core.
To make good on our commitment to sustainability, Tregenesis has joined the world’s leading companies to reduce GHG emissions. Climate change presents a material threat to human health and environments worldwide.
Tregenesis is dedicated to developing innovative medicines for life-threatening illnesses – and we recognize that it takes more than medicine to address challenges people and communities face.
At Tregenesis Sciences, we pride ourselves on our passion for patients. This passion, as well as our focused concentration on developing treatments for patients living with gastrointestinal diseases, is a key driver for our success. Established and led by specialty pharmaceutical executives with extensive experience in the global market. Tregenesis Sciences is committed to improving the lives of patients with gastrointestinal diseases.
We at Tregenesis are committed to honest and ethical business conduct in all of our activities, consistent with all applicable laws and the highest professional standards. We treat our employees and business partners with fairness and respect, rewarding loyalty, honesty, entrepreneurship and outstanding performance. We focus on realising the core values.
“At Tregenesis we are dedicated to advancing our employees’ skills and supporting them with their professional development. We encourage individuals’ involvement in all aspects of the business in which they are interested, to gain a deeper insight into the full picture. In order to do this, we offer a variety of leadership training and support with further education. We support and collaborate with healthcare professionals around the world to continuously evolve the understanding in the field of Gastroenterology and other specialist therapeutic areas. We deliver high quality medicines and educational support that improve patient lives. We take pride in our unique culture, that is based on our corporate values, guiding us in our everyday business and allowing our diverse workforce to develop and deliver their full potential. We treat our employees as well as our business partners with fairness and respect. In striving towards our Vision 2030, we always demonstrate passion, rewarding entrepreneurial spirit and outstanding performance. We encourage our employees to see the bigger picture, challenge the status quo and embrace change.”
Since its foundation, Tregenesis has been committed to improving care for people with gastrointestinal (GI) diseases. We collaborate with healthcare professionals and GI-experts to develop and market medicines for the treatment of diseases of the digestive system.
Our specific focus on the digestive system means we have in-depth knowledge of the challenges that gastroenterologists and hepatologists face on a daily basis. It also helps us look for innovative ways to improve care and quality of life for the 5–6 million people who live with inflammatory bowel diseases worldwide.
Inflammatory bowel disease (IBD) is a group of conditions where the body’s own immune system attacks parts of the digestive tract. IBD is a chronic, incurable disease. Currently, IBD affects around 5–6 million people worldwide, and the global prevalence is expected to rise over the next decade 2. The two main types of IBD are Crohn’s disease (CD), which can occur anywhere along the digestive tract, and ulcerative colitis (UC), which is limited to the large intestine and rectum. Symptoms vary and can include abdominal pain, fever, diarrhoea, blood in stool and weight loss.
Ulcerative colitis (UC) is an inflammatory bowel disease that involves chronic inflammation of the lining of the large bowel. Unlike Crohn’s disease, which can occur anywhere along the digestive tract, UC only affects the colon and rectum. UC causes swelling of the intestinal wall, in addition to ulceration of the large intestine. Symptoms vary, but often include abdominal pain and diarrhoea. UC is a chronic debilitating disease that may lead to life-threatening complications. UC treatment is aimed at reducing symptoms, controlling flares and maintaining remission1.
Crohn’s disease (CD) is an inflammatory bowel disease that is caused by the chronic inflammation of the digestive tract. Symptoms vary, but often include abdominal pain, severe diarrhoea, fatigue, weight loss and malnutrition. Inflammation caused by CD can involve different areas of the gastrointestinal tract (from the mouth to the anus), but most commonly affects the lower part of the small intestine, including the terminal ileum and ascending colon. In CD, swelling and scar tissue can lead to constriction of the intestine. CD is a chronic debilitating disease that may lead to life-threatening complications. Currently there is no permanent pharmacological or surgical cure.
Microscopic colitis (MC) is an inflammation of the colon that causes chronic, non-bloody watery diarrhoea. Patients with MC can experience abdominal pain, faecal incontinence and weight loss; symptoms that heavily impair their quality of life. Association of MC with autoimmune diseases, such as rheumatism, thyroid disease, diabetes or coeliac disease is not uncommon. The colonic mucosa of patients with MC appears normal on visual inspection by colonoscopy. For this reason, patients are often misdiagnosed with IBS.
Clostridioides difficile infections (CDI), also known as C. difficile-associated diarrhoea (CDAD), is an infection caused by the toxins of the spore-forming bacterium Clostridioides difficile. Symptoms vary, but often include diarrhoea stomach pain and fever. Signs and symptoms usually develop within five to 10 days after starting a course of antibiotics, but may occur as soon as the first day or up to two months later. The infection most often affects older adults in hospitals or in long-term care facilities and characteristically occurs after use of antibiotics.
Irritable bowel syndrome (IBS) is a chronic condition of the digestive system. This condition causes abdominal pain and altered bowel habits. The main complaints are either frequent, watery bowel movements (diarrhoea) or not frequent enough bowel movements (constipation). In some patients these symptoms may switch between diarrhoea and constipation. IBS is the most commonly diagnosed gastrointestinal condition and is second only to the common cold as a cause of absence from work. An estimated 10–20% of people in the general population experience symptoms of IBS.
Colorectal cancer (CRC) is a major health problem in the world as it has been described as one of the most common causes of cancer-related death. An early diagnosis is crucial for patient survival and also their quality of life. Effective CRC screening and diagnosis usually relies on a total colonoscopy, which is widely used for the diagnosis and treatment control of colon disorders (e.g. large-bowel symptoms, iron deficiency, anaemia, postpolypectomy as well as diagnosis and surveillance in inflammatory bowel disease). Prior to a colonoscopy, bowel cleanser preparations have to be applied.
“It is our strong belief that the success of any company lies in its capability to acquire, develop and retain dedicated and highly-skilled professionals, who work passionately together. We are doing this by offering our employees a climate of responsibility, accountability and respect where every employee has the opportunity to excel and develop to their full potential.”
Work with us